At $1.8 billion, Q2 device financing nearly doubled the Q1 total, mainly from an increase in IPOs and early VC rounds, and acquisitions were slightly higher at $4.7 billion. Diagnostics funding also increased to $784 million from Q1's $597 million, and Danaher's monster $13.8 billion buy of life sciences company Pall headlined the second quarter's $15.6 billion total in diagnostics M&A activity.

After the establishment of its first overseas subsidiary in Taiwan early this year, Medytox has set up a joint venture with China's Bloomage BioTechnology to sell its botulinum toxin products and hyaluronic acid fillers in China. The South Korean biopharma company is aiming to establish more subsidiaries in other major Asian countries as part of plans to directly sell its products in the region.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced May-June 2015.